JP2009532326A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009532326A5 JP2009532326A5 JP2008554385A JP2008554385A JP2009532326A5 JP 2009532326 A5 JP2009532326 A5 JP 2009532326A5 JP 2008554385 A JP2008554385 A JP 2008554385A JP 2008554385 A JP2008554385 A JP 2008554385A JP 2009532326 A5 JP2009532326 A5 JP 2009532326A5
- Authority
- JP
- Japan
- Prior art keywords
- zinc finger
- finger protein
- nucleic acid
- acid encoding
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77241706P | 2006-02-09 | 2006-02-09 | |
| US80323406P | 2006-05-25 | 2006-05-25 | |
| PCT/US2007/003538 WO2007092609A2 (en) | 2006-02-09 | 2007-02-09 | Method for treating peripheral arterial disease with zinc finger proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009532326A JP2009532326A (ja) | 2009-09-10 |
| JP2009532326A5 true JP2009532326A5 (enExample) | 2010-03-25 |
Family
ID=38345833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008554385A Pending JP2009532326A (ja) | 2006-02-09 | 2007-02-09 | ジンクフィンガータンパク質により末梢動脈疾患を処置するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090305977A1 (enExample) |
| EP (1) | EP1993586A4 (enExample) |
| JP (1) | JP2009532326A (enExample) |
| AU (1) | AU2007212260A1 (enExample) |
| CA (1) | CA2641198A1 (enExample) |
| WO (1) | WO2007092609A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102766359B1 (ko) * | 2021-04-07 | 2025-02-14 | (주)리젠이노팜 | 세포 투과성 펩타이드 변이체 및 이의 용도 |
| US20250043269A1 (en) | 2021-11-03 | 2025-02-06 | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad | Precise Genome Editing Using Retrons |
| WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| AU2023329392A1 (en) | 2022-08-25 | 2025-02-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| EP4771154A2 (en) | 2023-09-01 | 2026-07-08 | Renagade Therapeutics Management Inc. | Gene editing systems, compositions, and methods for treatment of vexas syndrome |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5693622A (en) * | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| US6140466A (en) * | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| CN1295617A (zh) * | 1998-02-06 | 2001-05-16 | 科莱特诺医疗公司 | 血管生成因子－血管内皮细胞生长因子vegf的突变体 |
| US6599692B1 (en) * | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
| US6534261B1 (en) * | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| WO2002046412A2 (en) * | 2000-12-07 | 2002-06-13 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
| US7067317B2 (en) * | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
| US7223740B2 (en) * | 2001-05-23 | 2007-05-29 | Fornix Biosciences N.V. | Vectors for enhanced expression of VEGF for atrial disease treatment |
| WO2004108167A1 (en) * | 2003-06-05 | 2004-12-16 | Gencell Sas | Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes associated angiogenic defects |
| CN1836048A (zh) * | 2003-06-10 | 2006-09-20 | 图尔金株式会社 | 可转导的dna结合蛋白 |
| ATE418346T1 (de) * | 2004-04-08 | 2009-01-15 | Sangamo Biosciences Inc | Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen |
-
2007
- 2007-02-09 AU AU2007212260A patent/AU2007212260A1/en not_active Abandoned
- 2007-02-09 US US12/278,967 patent/US20090305977A1/en not_active Abandoned
- 2007-02-09 WO PCT/US2007/003538 patent/WO2007092609A2/en not_active Ceased
- 2007-02-09 CA CA002641198A patent/CA2641198A1/en not_active Abandoned
- 2007-02-09 JP JP2008554385A patent/JP2009532326A/ja active Pending
- 2007-02-09 EP EP07763713A patent/EP1993586A4/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Torres-Espín et al. | Eliciting inflammation enables successful rehabilitative training in chronic spinal cord injury | |
| Trakhtenberg et al. | Zinc chelation and Klf9 knockdown cooperatively promote axon regeneration after optic nerve injury | |
| Yehya et al. | Angiogenesis: Managing the culprits behind tumorigenesis and metastasis | |
| Ye et al. | Synthetic therapeutic gene circuits in mammalian cells | |
| JP2020040969A5 (enExample) | ||
| ES2653615T3 (es) | Pluralidad de dosis de LAG-3 recombinante para su uso en la provocación de una respuesta inmunitaria de monocitos | |
| JP2014169326A5 (enExample) | ||
| Bai et al. | Tongxinluo improves cardiac function and ameliorates ventricular remodeling in mice model of myocardial infarction through enhancing angiogenesis | |
| Rubanyi | Mechanistic, technical, and clinical perspectives in therapeutic stimulation of coronary collateral development by angiogenic growth factors | |
| Dickinson et al. | A critical role for Egr-1 during vascular remodelling in pulmonary arterial hypertension | |
| Ye et al. | Synthetic mammalian gene circuits for biomedical applications | |
| Chung et al. | LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways | |
| JP2012041342A5 (enExample) | ||
| JP2010526153A5 (enExample) | ||
| JP2010500370A5 (enExample) | ||
| ES2717661T3 (es) | Terapia de combinación para el tratamiento de las enfermedades autoinmunes | |
| RU2010145048A (ru) | On01910.na, усиливающий активность химиотерапевтического агента в резистентных к лекарственным средствам опухолях | |
| JP2016501528A5 (enExample) | ||
| Huang et al. | Met-CCL5 represents an immunotherapy strategy to ameliorate rabies virus infection | |
| Parthiban et al. | Macrophage-derived CCL24 promotes cardiac fibrosis via fibroblast CCR3 | |
| Macagno et al. | New treatment directions for IPF: current status of ongoing and upcoming clinical trials | |
| Lu et al. | Hiv/aids curable study: new forms of therapeutic trinity | |
| RU2017126212A (ru) | Композиция | |
| CN101920015A (zh) | 一种治疗癌症的药物组合物 | |
| Ma et al. | Tongxinluo mitigates atherogenesis by regulating angiogenic factors and inhibiting vasa vasorum neovascularization in apolipoprotein E-deficient mice |